Compound · clinical trials

Paraplatin clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 90 trials in our Canada, Mexico, Israel, Spain, South Korea, USA, Australia, Japan, Taiwan, Italy, France, Germany, China, Poland, Turkey, UK, Belgium, Brazil, Netherlands, Norway, Ireland, Denmark, Czechia, Switzerland, India, Sweden, Austria, Egypt, Singapore and Portugal registers that name Paraplatin as an intervention. Synced 9 Nov 2026

90Current trials

45Recruiting now

28Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Paraplatin is named as an intervention in 90 current clinical trials in our Canada, Mexico, Israel, Spain, South Korea, USA, Australia, Japan, Taiwan, Italy, France, Germany, China, Poland, Turkey, UK, Belgium, Brazil, Netherlands, Norway, Ireland, Denmark, Czechia, Switzerland, India, Sweden, Austria, Egypt, Singapore and Portugal registers. 45 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (23). The most-studied condition is Carcinoma, Non-Small-Cell Lung.

Patient leaflets for Paraplatin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting4550%
Not yet open11%
Active, closed4449%

Trials by phase

Phase 34550%
Phase 23337%
Phase 1/267%
Phase 2/322%
Phase 122%
Observational11%
Not applicable11%

Clinical trials of Paraplatin

90 trials

Study	Phase	Status	Lead sponsor	Registers
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181 · ClinicalTrials.gov ↗ · Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor	Phase 3	Recruiting	Children's Oncology Group	India, Canada, Mexico, Japan, Australia, Israel
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma NCT04166409 · ClinicalTrials.gov ↗ · Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Norway, Mexico, Israel
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Urothelial Carcinoma	Phase 3	Recruiting	University Health Network, Toronto	Canada
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8	Phase 3	Recruiting	SWOG Cancer Research Network	Mexico, Israel
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) NCT06401330 · Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor	Phase 3	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. NCT06431633 · ClinicalTrials.gov ↗ · Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma	Phase 3	Recruiting	Fundación GECP	Spain
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer NCT07061977 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico, Israel
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer NCT07198074 · ClinicalTrials.gov ↗ · Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin NCT07441681 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma	Phase 3	Recruiting	NRG Oncology	Mexico
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% NCT03351842 · ClinicalTrials.gov ↗ · Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT NCT04322318 · ClinicalTrials.gov ↗ · Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor	Phase 2	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
Folfox+Irinotecan+Chemort In Esophageal Cancer NCT04656041 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer	Phase 2	Recruiting	Massachusetts General Hospital	Israel
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma NCT04671667 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT NCT04684368 · ClinicalTrials.gov ↗ · Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Using ctDNA to Determine Therapies for Lung Cancer NCT04966663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA	Phase 2	Recruiting	University Health Network, Toronto	Canada
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma NCT05456256 · Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	Lantern Pharma Inc	USA, Japan, Taiwan
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma NCT05504291 · ClinicalTrials.gov ↗ · Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Singapore, Australia
Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Breast Cancer	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma NCT06368817 · ClinicalTrials.gov ↗ · Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors NCT06528691 · ClinicalTrials.gov ↗ · High Grade Glioma, CNS Tumor	Phase 2	Recruiting	St. Jude Children's Research Hospital	Brazil
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907 · Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey, Taiwan, Israel
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, South Korea, Taiwan
PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer	Phase 2	Recruiting	Fundación GECP	Spain
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) NCT07153445 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer	Phase 2	Recruiting	Fundación GECP	Spain
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC NCT07405190 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell)	Phase 2	Recruiting	Massachusetts General Hospital	Israel
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors NCT02813135 · ClinicalTrials.gov ↗ · Pediatric Cancer	Phase 1/2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Spain, Italy, Netherlands, Denmark
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · Carcinoma, Non-Small-Cell Lung	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Canada, South Korea, Taiwan, Israel
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI NCT04954599 · ClinicalTrials.gov ↗ · Unspecified Adult Solid Tumor, Protocol Specific	Phase 1/2	Recruiting	Maastricht University Medical Center	Spain, Netherlands, Belgium
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, Germany, Spain, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc	USA
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer NCT06385080 · Squamous Cell Carcinoma of Head and Neck	Phase 1/2	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Poland, Japan, South Korea, Taiwan
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer	Phase 1	Recruiting	Shanghai Jiao Tong University School of Medicine	China, Japan
Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487 · ClinicalTrials.gov ↗ · Stage IIIA Non-small Cell Lung Cancer	Observational	Recruiting	Fundación GECP	Spain
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer NCT05794659 · Advanced Ovarian Cancer	Phase 2	Not yet open	Aston Sci. Inc	USA
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer NCT00565851 · ClinicalTrials.gov ↗ · Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Japan, South Korea
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT00588770 · ClinicalTrials.gov ↗ · Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer NCT01081262 · ClinicalTrials.gov ↗ · Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer NCT01167712 · ClinicalTrials.gov ↗ · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, South Korea, Israel
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma NCT01820858 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Ding Ma	China
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma NCT02176967 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors NCT02375204 · Germ Cell Tumor, Teratoma, Choriocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Australia
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 · ClinicalTrials.gov ↗ · Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma	Phase 3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02446600 · ClinicalTrials.gov ↗ · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer NCT02488967 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative	Phase 3	Active, closed	NRG Oncology	Norway, Canada, Israel, Egypt
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer NCT03793179 · ClinicalTrials.gov ↗ · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) NCT03811002 · ClinicalTrials.gov ↗ · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Japan, Egypt
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma NCT03871257 · ClinicalTrials.gov ↗ · Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer NCT03914612 · ClinicalTrials.gov ↗ · Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea, Israel, Egypt
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04095364 · Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma	Phase 3	Active, closed	NRG Oncology	Ireland, Canada, Mexico, South Korea, Egypt
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery NCT04498117 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Active, closed	CanariaBio Inc	USA, India, Spain, Italy, Belgium, Czechia, Canada, Brazil, Mexico, South Korea, Taiwan
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy NCT04564157 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adjuvant Chemotherapy	Phase 3	Active, closed	Fundación GECP	Spain
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer NCT04595565 · HER2-negative Breast Cancer, Triple Negative Breast Cancer	Phase 3	Active, closed	GBG Forschungs GmbH	Ireland, Germany, France, Spain, Belgium, Switzerland, Austria
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma NCT05256225 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, South Korea
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma NCT06097728 · Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma NCT06230224 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	Spain, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers NCT05063552 · ClinicalTrials.gov ↗ · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer NCT05800015 · Non-small Cell Lung Cancer	Phase 2/3	Active, closed	Regeneron Pharmaceuticals	USA, Turkey, Canada, Mexico, South Korea, Taiwan, Australia, Israel
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer NCT00977574 · ClinicalTrials.gov ↗ · Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer NCT01898494 · ClinicalTrials.gov ↗ · Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC NCT02259621 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Canada
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas NCT02595424 · ClinicalTrials.gov ↗ · Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT03517969 · ClinicalTrials.gov ↗ · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
9-ING-41 in Patients With Advanced Cancers NCT03678883 · Cancer, Pancreatic Cancer, Sarcoma	Phase 2	Active, closed	Actuate Therapeutics Inc	USA, France, Spain, Netherlands, Belgium, Portugal, Canada
NADIM II: Neo-Adjuvant Immunotherapy NCT03838159 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases NCT05012254 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · Non-small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Canada, South Korea, Taiwan, Australia
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer NCT05198830 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer NCT05605535 · Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms	Phase 2	Active, closed	CanariaBio Inc	India
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors NCT05684276 · ClinicalTrials.gov ↗ · NSCLC, Pancoast Tumor	Phase 2	Active, closed	Fundación GECP	Spain
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery NCT06161441 · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Regeneron Pharmaceuticals	USA, Germany, France, Spain, Italy, Turkey, South Korea, Taiwan, Australia
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol NCT03997370 · ClinicalTrials.gov ↗ · Malignant Solid Neoplasm	Phase 1	Active, closed	NRG Oncology	Israel
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Paraplatin

197 conditions

Carcinoma, Non-Small-Cell Lung5 Non-small Cell Lung Cancer4 Ovarian Cancer4 Non Small Cell Lung Cancer4Stage III Lung Cancer AJCC v84Endometrial Cancer3Lung Non-Squamous Non-Small Cell Carcinoma3Neuroblastoma3Endometrial Clear Cell Adenocarcinoma3Cervical Cancer2 HER2-negative Breast Cancer2 Endometrial Neoplasms2

All 197 conditions

Condition (as registered)	Trials
Carcinoma, Non-Small-Cell Lung	5
Non-small Cell Lung Cancer	4
Ovarian Cancer	4
Non Small Cell Lung Cancer	4
Stage III Lung Cancer AJCC v8	4
Endometrial Cancer	3
Lung Non-Squamous Non-Small Cell Carcinoma	3
Neuroblastoma	3
Endometrial Clear Cell Adenocarcinoma	3
Cervical Cancer	2
HER2-negative Breast Cancer	2
Endometrial Neoplasms	2
Germ Cell Tumor	2
Choriocarcinoma	2
Germinoma	2
Lung Adenocarcinoma	2
Triple Negative Breast Neoplasms	2
Breast Neoplasms	2
Brain Metastases, Adult	2
Lung Diseases	2
Non-Small Cell Lung Cancer	2
Stage II Lung Cancer AJCC v8	2
Estrogen Receptor Negative	2
HER2/Neu Negative	2
Progesterone Receptor Negative	2
Stage IIB Lung Cancer AJCC v8	2
Fallopian Tube Clear Cell Adenocarcinoma	2
Fallopian Tube Transitional Cell Carcinoma	2
Stage IIIB Lung Cancer AJCC v8	2
Ganglioneuroblastoma	2
Ganglioneuroblastoma, Nodular	2
Low Grade Glioma	2
Fallopian Tube Endometrioid Adenocarcinoma	2
Fallopian Tube Mucinous Adenocarcinoma	2
Endometrial Dedifferentiated Carcinoma	2
Endometrial Endometrioid Adenocarcinoma	2
Recurrent Hypopharyngeal Squamous Cell Carcinoma	2
Recurrent Laryngeal Squamous Cell Carcinoma	2
Low Grade Fallopian Tube Serous Adenocarcinoma	1
Ovarian Low Grade Serous Adenocarcinoma	1
Primary Peritoneal Low Grade Serous Adenocarcinoma	1
Stage II Fallopian Tube Cancer AJCC v8	1
Small Cell Lung Carcinoma	1
Triple Negative Breast Cancer	1
Teratoma	1
Unresectable Pleural Mesothelioma	1
Lung Neoplasms	1
Lung Squamous Cell Carcinoma	1
Gastric Cancer	1
Metastatic Castration-resistant Prostate Cancer	1
Squamous Cell Carcinoma of Head and Neck	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Advanced Ovarian Cancer	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
Lung Neoplasm Malignant	1
Resectable Non-small Cell Lung Cancer	1
Carcinoma, Ovarian Epithelial	1
Ovarian Neoplasms	1
Ovarian Serous Adenocarcinoma	1
Breast Cancer	1
Adenocarcinoma of Lung	1
Cancer	1
Pancreatic Cancer	1
Sarcoma	1
Renal Cancer	1
Ovarian Neoplasm Epithelial	1
Fallopian Tube Neoplasms	1
Peritoneal Carcinoma	1
Childhood Extracranial Germ Cell Tumor	1
Extragonadal Embryonal Carcinoma	1
Malignant Germ Cell Tumor	1
Advanced Breast Cancer	1
Chemotherapy, Adjuvant	1
Lung Adenocarcinoma, Stage I	1
Treatment	1
Histological Type of Neoplasm	1
Recurrent Non-small Cell Lung Cancer	1
Pediatric Cancer	1
Stage IIIA Lung Cancer	1
Stage IIIB Lung Cancer	1
B-Cell Non-Hodgkin Lymphoma (B-NHL)	1
Stage IIIA Non-small Cell Lung Cancer	1
NSCLC	1
Pancoast Tumor	1
Non Small Cell Lung Cancer Metastatic	1
Stage IV Non-small Cell Lung Cancer	1
Stage III Non-small Cell Lung Cancer	1
Unspecified Adult Solid Tumor, Protocol Specific	1
Adjuvant Chemotherapy	1
Lung Cancer	1
Resectable Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Limited Stage Lung Small Cell Carcinoma	1
Stage I Lung Cancer AJCC v8	1
Breast Adenocarcinoma	1
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	1
Stage II Lung Non-Small Cell Cancer AJCC v7	1
Stage IIA Lung Cancer AJCC v8	1
Central Nervous System Nongerminomatous Germ Cell Tumor	1
Embryonal Carcinoma	1
Immature Teratoma	1
Locally Advanced Lung Non-Small Cell Carcinoma	1
Basal Ganglia Germinoma	1
Diabetes Insipidus	1
Pineal Region Germinoma	1
Fallopian Tube Undifferentiated Carcinoma	1
Ovarian Clear Cell Adenocarcinoma	1
Stage IIIC Lung Cancer AJCC v8	1
Stage IV Lung Cancer AJCC v8	1
Anaplastic Kidney Wilms Tumor	1
Recurrent Kidney Wilms Tumor	1
Stage II Kidney Wilms Tumor	1
Stage III Kidney Wilms Tumor	1
Bladder Cancer	1
Bladder Urothelial Carcinoma	1
Low Grade Astrocytoma	1
Metastatic Low Grade Astrocytoma	1
Metastatic Low Grade Glioma	1
Localized Resectable Neuroblastoma	1
Localized Unresectable Neuroblastoma	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Hepatoblastoma	1
Neurofibromatosis Type 1	1
Visual Pathway Glioma	1
Metastatic Nasopharyngeal Carcinoma	1
Recurrent Nasopharyngeal Carcinoma	1
Stage IV Nasopharyngeal Carcinoma AJCC v8	1
Bilateral Retinoblastoma	1
Childhood Intraocular Retinoblastoma	1
Group D Retinoblastoma	1
Stage I Retinoblastoma	1
Ovarian Brenner Tumor	1
Endometrial Mixed Cell Adenocarcinoma	1
Complete Surgical Resection	1
Circulating Tumor DNA	1
Stage I Mixed Cell Type Kidney Wilms Tumor	1
Stage II Mixed Cell Type Kidney Wilms Tumor	1
Stage III Mixed Cell Type Kidney Wilms Tumor	1
Stage IV Mixed Cell Type Kidney Wilms Tumor	1
High Grade Glioma	1
CNS Tumor	1
Anatomic Stage I Breast Cancer AJCC v8	1
Anatomic Stage II Breast Cancer AJCC v8	1
Anatomic Stage IIIA Breast Cancer AJCC v8	1
Anatomic Stage IIIB Breast Cancer AJCC v8	1
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma	1
Locally Advanced Laryngeal Squamous Cell Carcinoma	1
Locally Advanced Oral Cavity Squamous Cell Carcinoma	1
Locally Advanced Oropharyngeal Squamous Cell Carcinoma	1
Borderline Ovarian Mucinous Tumor	1
Ovarian Mucinous Cystadenocarcinoma	1
Recurrent Fallopian Tube Carcinoma	1
Recurrent Ovarian Carcinoma	1
Invasive Breast Carcinoma	1
Endometrial Carcinoma	1
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Metastatic Head and Neck Squamous Cell Carcinoma	1
Metastatic Hypopharyngeal Squamous Cell Carcinoma	1
Metastatic Laryngeal Squamous Cell Carcinoma	1
Human Papilloma Virus Infection	1
Stage III Squamous Cell Carcinoma of the Oropharynx	1
Stage IVA Squamous Cell Carcinoma of the Oropharynx	1
Stage IVB Squamous Cell Carcinoma of the Oropharynx	1
Recurrent Lung Non-Small Cell Carcinoma	1
Stage IIIA Lung Cancer AJCC v8	1
Locally Advanced Cervical Adenocarcinoma	1
Locally Advanced Cervical Adenosquamous Carcinoma	1
Locally Advanced Cervical Squamous Cell Carcinoma	1
Stage IIIA Cervical Cancer FIGO 2018	1
Recurrent Head and Neck Squamous Cell Carcinoma	1
Recurrent Oral Cavity Squamous Cell Carcinoma	1
Clear Cell Adenocarcinoma	1
Advanced Endometrial Carcinoma	1
Recurrent Endometrial Carcinoma	1
Endometrial Adenocarcinoma	1
Endometrial Adenosquamous Carcinoma	1
Endometrial Serous Adenocarcinoma	1
Gastric Neuroendocrine Carcinoma	1
Intestinal Neuroendocrine Carcinoma	1
Pancreatic Neuroendocrine Carcinoma	1
Neck Squamous Cell Carcinoma of Unknown Primary	1
Recurrent Laryngeal Verrucous Carcinoma	1
Lung Cancer (NSCLC)	1
Lung Cancer Non-Small Cell Cancer (NSCLC)	1
Lung Cancer (Non-Small Cell)	1
Lung Cancer - Non Small Cell	1
Malignant Solid Neoplasm	1
Gastroesophageal Junction Adenocarcinoma	1
Esophagogastric Cancer	1
Castration-Resistant Prostate Carcinoma	1
Metastatic Prostate Carcinoma	1
Stage IV Prostate Cancer AJCC v8	1
Lung Large Cell Carcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in Canada	40	22
Clinical trials in Mexico	38	14
Clinical trials in Israel	37	20
Clinical trials in Spain	34	18
Clinical trials in South Korea	26	11
Clinical trials in USA	25	14
Clinical trials in Australia	24	14
Clinical trials in Japan	20	12
Clinical trials in Taiwan	20	13
Clinical trials in Italy	19	10
Clinical trials in France	17	9
Clinical trials in Germany	16	8
Clinical trials in China	16	11
Clinical trials in Poland	15	10
Clinical trials in Turkey	15	7
Clinical trials in UK	14	9
Clinical trials in Belgium	13	7
Clinical trials in Brazil	11	7
Clinical trials in Netherlands	11	6
Clinical trials in Norway	9	3
Clinical trials in Ireland	7	2
Clinical trials in Denmark	7	4
Clinical trials in Czechia	6	3
Clinical trials in Switzerland	6	3
Clinical trials in India	5	3
Clinical trials in Sweden	5	4
Clinical trials in Austria	5	3
Clinical trials in Egypt	4	0
Clinical trials in Singapore	4	3
Clinical trials in Portugal	3	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Paraplatin trials

How many clinical trials are testing Paraplatin?

90 current trials in our Canada, Mexico, Israel, Spain, South Korea, USA, Australia, Japan, Taiwan, Italy, France, Germany, China, Poland, Turkey, UK, Belgium, Brazil, Netherlands, Norway, Ireland, Denmark, Czechia, Switzerland, India, Sweden, Austria, Egypt, Singapore and Portugal registers name Paraplatin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Paraplatin trials recruiting patients?

Yes. 45 of the 90 trials are recruiting: 22 with sites in Canada, 14 with sites in Mexico, 20 with sites in Israel, 18 with sites in Spain, 11 with sites in South Korea, 14 with sites in USA, 14 with sites in Australia, 12 with sites in Japan, 13 with sites in Taiwan, 10 with sites in Italy, 9 with sites in France, 8 with sites in Germany, 11 with sites in China, 10 with sites in Poland, 7 with sites in Turkey, 9 with sites in UK, 7 with sites in Belgium, 7 with sites in Brazil, 6 with sites in Netherlands, 3 with sites in Norway, 2 with sites in Ireland, 4 with sites in Denmark, 3 with sites in Czechia, 3 with sites in Switzerland, 3 with sites in India, 4 with sites in Sweden, 3 with sites in Austria, 3 with sites in Singapore and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Paraplatin clinical trials?

National Cancer Institute (NCI) (23), Merck Sharp & Dohme LLC (12), Children's Oncology Group (9) and Fundación GECP (8), among 28 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Paraplatin clinical trials in Ireland?

Yes. 7 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Paraplatin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Paraplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Paraplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.